Gene Deficiency in Activating Fcγ Receptors Influences the Macrophage Phenotypic Balance and Reduces Atherosclerosis in Mice

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Mallavia, Beñat ^a   Oguiza, Ainhoa ^a   Lopez Franco, Oscar ^a,b   Recio, Carlota ^a   Ortiz Muñoz, Guadalupe ^a,c   Lazaro, Iolanda ^a   Lopez Parra, Virginia ^a   Egido, Jesus ^a   Gomez Guerrero, Carmen ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; FC RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; OXIDIZED LOW DENSITY LIPOPROTEIN; APOLIPOPROTEIN E; LIPID; LOW DENSITY LIPOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; APOPTOSIS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; BONE MARROW TRANSPLANTATION; CELL COUNT; CELL FUNCTION; CELL TRANSFORMATION; CONTROLLED STUDY; DISEASE COURSE; GENE EXPRESSION; HYPERLIPIDEMIA; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LIPID BLOOD LEVEL; MACROPHAGE; MALE; MONOCYTE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; REGULATORY T LYMPHOCYTE; SMOOTH MUSCLE FIBER; T LYMPHOCYTE; TRANSCRIPTION INITIATION; ANIMAL; ATHEROSCLEROSIS; BLOOD; C57BL MOUSE; CYTOLOGY; DEFICIENCY; DISEASE MODEL; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; MORTALITY; PATHOLOGY; PATHOPHYSIOLOGY;

MURINAE; MUS;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BONE MARROW TRANSPLANTATION; COLLAGEN; DISEASE MODELS, ANIMAL; HYPERLIPIDEMIAS; LIPIDS; LIPOPROTEINS, LDL; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHENOTYPE; PLAQUE, ATHEROSCLEROTIC; RECEPTORS, IGG; T-LYMPHOCYTES;

EID: 84879252343     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066754     Document Type: Article

References (53)

1. Ross R, (1999) Atherosclerosis-an inflammatory disease. N Engl J Med 340: 115-126.
2. Yan ZQ, Hansson GK, (2007) Innate immunity, macrophage activation, and atherosclerosis. Immunol Rev 219: 187-203.
3. Mantovani A, Garlanda C, Locati M, (2009) Macrophage diversity and polarization in atherosclerosis: a question of balance. Arterioscler Thromb Vasc Biol 29: 1419-1423.
4. Swirski FK, Weissleder R, Pittet MJ, (2009) Heterogeneous in vivo behavior of monocyte subsets in atherosclerosis. Arterioscler Thromb Vasc Biol 29: 1424-1432.
5. Martinez FO, Helming L, Gordon S, (2009) Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 27: 451-483.
6. Nilsson J, Hansson GK, (2008) Autoimmunity in atherosclerosis: a protective response losing control? J Intern Med 263: 464-478.
7. Maggi E, Chiesa R, Melissano G, Castellano R, Astore D, et al. (1994) LDL oxidation in patients with severe carotid atherosclerosis. A study of in vitro and in vivo oxidation markers. Arterioscler Thromb 14: 1892-1899.
8. Lopes-Virella MF, Hunt KJ, Baker NL, Lachin J, Nathan DM, et al. (2011) Levels of oxidized LDL and advanced glycation end products-modified LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes. Diabetes 60: 582-589.
9. Virella G, Lopes-Virella MF, (2008) Atherogenesis and the humoral immune response to modified lipoproteins. Atherosclerosis 200: 239-246.
10. Takai T, (2005) Fc receptors and their role in immune regulation and autoimmunity. J Clin Immunol 25: 1-18.
11. Nimmerjahn F, Ravetch JV, (2006) Fcgamma receptors: old friends and new family members. Immunity 24: 19-28.
12. Ratcliffe NR, Kennedy SM, Morganelli PM, (2001) Immunocytochemical detection of Fcgamma receptors in human atherosclerotic lesions. Immunol Lett 77: 169-174.
13. Pfeiffer JR, Howes PS, Waters MA, Hynes ML, Schnurr PP, et al. (2001) Levels of expression of Fcgamma receptor IIA (CD32) are decreased on peripheral blood monocytes in patients with severe atherosclerosis. Atherosclerosis 155: 211-218.
14. Gavasso S, Nygard O, Pedersen ER, Aarseth JH, Bleie O, et al. (2005) Fcgamma receptor IIIA polymorphism as a risk-factor for coronary artery disease. Atherosclerosis 180: 277-282.
15. Raaz D, Herrmann M, Ekici AB, Klinghammer L, Lausen B, et al. (2009) FcgammaRIIa genotype is associated with acute coronary syndromes as first manifestation of coronary artery disease. Atherosclerosis 205: 512-516.
16. Hernandez-Vargas P, Ortiz-Munoz G, Lopez-Franco O, Suzuki Y, Gallego-Delgado J, et al. (2006) Fcgamma receptor deficiency confers protection against atherosclerosis in apolipoprotein E knockout mice. Circ Res 99: 1188-1196.
17. Kelly JA, Griffin ME, Fava RA, Wood SG, Bessette KA, et al. (2010) Inhibition of arterial lesion progression in CD16-deficient mice: evidence for altered immunity and the role of IL-10. Cardiovasc Res 85: 224-231.
18. Zhao M, Wigren M, Duner P, Kolbus D, Olofsson KE, et al. (2010) FcgammaRIIB inhibits the development of atherosclerosis in low-density lipoprotein receptor-deficient mice. J Immunol 184: 2253-2260.
19. Ng HP, Burris RL, Nagarajan S, (2011) Attenuated atherosclerotic lesions in apoE-Fcgamma-chain-deficient hyperlipidemic mouse model is associated with inhibition of Th17 cells and promotion of regulatory T cells. J Immunol 187: 6082-6093.
20. Lopez-Parra V, Mallavia B, Lopez-Franco O, Ortiz-Munoz G, Oguiza A, et al. (2012) Fcgamma receptor deficiency attenuates diabetic nephropathy. J Am Soc Nephrol 23: 1518-1527.
21. Nicoletti A, Kaveri S, Caligiuri G, Bariety J, Hansson GK, (1998) Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J Clin Invest 102: 910-918.
22. Xu Y, Arai H, Murayama T, Kita T, Yokode M, (2007) Hypercholesterolemia contributes to the development of atherosclerosis and vascular remodeling by recruiting bone marrow-derived cells in cuff-induced vascular injury. Biochem Biophys Res Commun 363: 782-787.
23. Suzuki Y, Gomez-Guerrero C, Shirato I, Lopez-Franco O, Gallego-Delgado J, et al. (2003) Pre-existing glomerular immune complexes induce polymorphonuclear cell recruitment through an Fc receptor-dependent respiratory burst: potential role in the perpetuation of immune nephritis. J Immunol 170: 3243-3253.
24. Piedrahita JA, Zhang SH, Hagaman JR, Oliver PM, Maeda N, (1992) Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci U S A 89: 4471-4475.
25. Lopez-Franco O, Hernandez-Vargas P, Ortiz-Munoz G, Sanjuan G, Suzuki Y, et al. (2006) Parthenolide modulates the NF-kappaB-mediated inflammatory responses in experimental atherosclerosis. Arterioscler Thromb Vasc Biol 26: 1864-1870.
26. Paigen B, Morrow A, Holmes PA, Mitchell D, Williams RA, (1987) Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis 68: 231-240.
27. Hernandez-Presa MA, Gomez-Guerrero C, Egido J, (1999) In situ non-radioactive detection of nuclear factors in paraffin sections by Southwestern histochemistry. Kidney Int 55: 209-214.
28. Ortiz-Munoz G, Martin-Ventura JL, Hernandez-Vargas P, Mallavia B, Lopez-Parra V, et al. (2009) Suppressors of cytokine signaling modulate JAK/STAT-mediated cell responses during atherosclerosis. Arterioscler Thromb Vasc Biol 29: 525-531.
29. Gomez-Guerrero C, Lopez-Franco O, Suzuki Y, Sanjuan G, Hernandez-Vargas P, et al. (2002) Nitric oxide production in renal cells by immune complexes: Role of kinases and nuclear factor-kappaB. Kidney Int 62: 2022-2034.
30. Zhou X, Paulsson G, Stemme S, Hansson GK, (1998) Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J Clin Invest 101: 1717-1725.
31. Smook ML, van LM, Heeringa P, Damoiseaux JG, Theunissen R, et al. (2008) Anti-oxLDL antibody isotype levels, as potential markers for progressive atherosclerosis in APOE and APOECD40L mice. Clin Exp Immunol 154: 264-269.
32. Horkko S, Bird DA, Miller E, Itabe H, Leitinger N, et al. (1999) Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest 103: 117-128.
33. Shoenfeld Y, Wu R, Dearing LD, Matsuura E, (2004) Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective? Circulation 110: 2552-2558.
34. Huang Y, Jaffa A, Koskinen S, Takei A, Lopes-Virella MF, (1999) Oxidized LDL-containing immune complexes induce Fc gamma receptor I-mediated mitogen-activated protein kinase activation in THP-1 macrophages. Arterioscler Thromb Vasc Biol 19: 1600-1607.
35. Ait-Oufella H, Herbin O, Bouaziz JD, Binder CJ, Uyttenhove C, et al. (2010) B cell depletion reduces the development of atherosclerosis in mice. J Exp Med 207: 1579-1587.
36. Swirski FK, Libby P, Aikawa E, Alcaide P, Luscinskas FW, et al. (2007) Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest 117: 195-205.
37. Combadiere C, Potteaux S, Rodero M, Simon T, Pezard A, et al. (2008) Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation 117: 1649-1657.
38. Takai T, (2002) Roles of Fc receptors in autoimmunity. Nat Rev Immunol 2: 580-592.
39. Sata M, Saiura A, Kunisato A, Tojo A, Okada S, et al. (2002) Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med 8: 403-409.
40. Yan P, Xia C, Duan C, Li S, Mei Z, (2011) Biological characteristics of foam cell formation in smooth muscle cells derived from bone marrow stem cells. Int J Biol Sci 7: 937-946.
41. Mineo C, Gormley AK, Yuhanna IS, Osborne-Lawrence S, Gibson LL, et al. (2005) FcgammaRIIB mediates C-reactive protein inhibition of endothelial NO synthase. Circ Res 97: 1124-1131.
42. Hakkinen T, Karkola K, Yla-Herttuala S, (2000) Macrophages, smooth muscle cells, endothelial cells, and T-cells express CD40 and CD40L in fatty streaks and more advanced human atherosclerotic lesions. Colocalization with epitopes of oxidized low-density lipoprotein, scavenger receptor, and CD16 (Fc gammaRIII). Virchows Arch 437: 396-405.
43. Zhou X, Robertson AK, Hjerpe C, Hansson GK, (2006) Adoptive transfer of CD4+ T cells reactive to modified low-density lipoprotein aggravates atherosclerosis. Arterioscler Thromb Vasc Biol 26: 864-870.
44. Mor A, Planer D, Luboshits G, Afek A, Metzger S, et al. (2007) Role of naturally occurring CD4+ CD25+ regulatory T cells in experimental atherosclerosis. Arterioscler Thromb Vasc Biol 27: 893-900.
45. Tedgui A, Mallat Z, (2006) Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 86: 515-581.
46. Gomez-Guerrero C, Mallavia B, Egido J, (2012) Targeting inflammation in cardiovascular diseases. still a neglected field? Cardiovasc Ther 30: e189-e197.
47. Plutzky J, (2001) Inflammatory pathways in atherosclerosis and acute coronary syndromes. Am J Cardiol 88: 10K-15K.
48. Khallou-Laschet J, Varthaman A, Fornasa G, Compain C, Gaston AT, et al. (2010) Macrophage plasticity in experimental atherosclerosis. PLoS One 5: e8852.
49. Pello OM, Silvestre C, De PM, Andres V, (2011) A glimpse on the phenomenon of macrophage polarization during atherosclerosis. Immunobiology 216: 1172-1176.
50. Munder M, Eichmann K, Modolell M, (1998) Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance: competitive regulation by CD4+ T cells correlates with Th1/Th2 phenotype. J Immunol 160: 5347-5354.
51. Edwards JP, Zhang X, Frauwirth KA, Mosser DM, (2006) Biochemical and functional characterization of three activated macrophage populations. J Leukoc Biol 80: 1298-1307.
52. Sironi M, Martinez FO, D'Ambrosio D, Gattorno M, Polentarutti N, et al. (2006) Differential regulation of chemokine production by Fcgamma receptor engagement in human monocytes: association of CCL1 with a distinct form of M2 monocyte activation (M2b, Type 2). J Leukoc Biol 80: 342-349.
53. Devaraj S, Jialal I, (2011) C-reactive protein polarizes human macrophages to an M1 phenotype and inhibits transformation to the M2 phenotype. Arterioscler Thromb Vasc Biol 31: 1397-1402.